On the Horizon- A Better ADT Treatment with Less Side Effects

GTx Inc. had a poster honored as one of the best posters at the 28th Annual European Association of Urology Congress held in Milan Italy March 15 2013. The poster presentation which had the very long title of “GTx-758 an ERa Agonist Reduces Serum Free Testosterone Lower than can be Achieved by Leuprolide with a Significantly Lower Rate of Hot Flashes in Men with Advanced Prostate Cancer” says it all. The actual presentation was held on Saturday March 16 2013 in Milan Italy and was a part of the session on New Therapies in Castration Resistant Prostate Cancer. The data [...]

GTx Receives clearance for New Capesaris Trials

GTx Inc. announced that FDA regulators will allow it to restart the clinical trials of its investigational prostate cancer drug Capesaris for men with castrate resistant advanced prostate cancer. They anticipate that the trials of Capesaris will begin during the third quarter of 2012. The trial is designed to evaluate Capesaris as a secondary treatment for advanced prostate cancer that no longer responds to hormone treatment, a condition known as being castrate resistant. The trial protocol will test three different doses of Capesaris on 75 men. In February the he FDA ordered GTx to stop the clinical trials of Capesaris [...]

Capesaris™ (GTx-758) Phase II Proof of Concept Trial – A New On the Horizon Drug To Watch

GTx, Inc. this weekend presented results of the Capesaris™ (GTx-758) proof of concept pharmacokinetic-pharmacodynamic (PK/PD) clinical trial treating men with advanced prostate cancer, at the Annual Meeting of the Society of Urologic Oncology. Capesaris is a novel oral selective estrogen receptor alpha agonist which GTx is developing for first line treatment of advanced prostate cancer. “As Capesaris advances from proof of concept into clinical trials in men with advanced prostate cancer, it is emerging as a promising drug candidate which represents a new approach to androgen deprivation therapy,” said Thomas Keane, M.D., Chairman and Professor of Urology at the Medical University of South Carolina. “Because of the mechanism of action through the estrogen receptor, Capesaris has the potential to suppress testosterone to castrate levels without previously documented problems of ADT such as bone loss and hot flashes. […]